Intravenous Immunoglobulin for Treatment of Severe Coronavirus Disease 19 (COVID-19) – A Literature Overview

por Rizvi, Syed, Kreuwel, Huub
Publicado 2021

Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig(®)) in the treatment of patients with primary immunodeficiencies

por Kobayashi, Roger H, Litzman, Jiří, Melamed, Isaac, Mandujano, J Fernando, Kobayashi, Ai Lan, Ritchie, Bruce, Geng, Bob, Atkinson, T Prescott, Rehman, Syed, Höller, Sonja, Turpel-Kantor, Eva, Kreuwel, Huub, Speer, J C, Gupta, Sudhir
Publicado 2022

Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens

por Gupta, Sudhir, DeAngelo, James, Melamed, Isaac, Walter, Jolan E., Kobayashi, Ai-Lan, Bridges, Tracy, Sublett, J. Wesley, Bernstein, Jonathan A., Koterba, Alan, Manning, Michael, Maltese, Joanna, Hoeller, Sonja, Turpel-Kantor, Eva, Kreuwel, Huub, Kobayashi, Roger H.
Publicado 2023